Wet Age-related Macular Degeneration (Wet AMD) is a type of Age-related Macular Degeneration (AMD) characterized by sudden central vision loss caused by abnormal blood vessels, which bleed or leak fluid that may swell and damage the macula. Age-related Macular Degeneration is among the most prominent causes of severe, irreversible blindness globally, profoundly affecting individuals' quality of life. Wet AMD is also referred to as neovascular AMD.
&nbsp;
Wet Age-related Macular Degeneration Epidemiological Segmentation
The Epidemiological Segmentation of Wet Age-related Macular Degeneration in 7MM from 2018 to 2030 is segmented into:-
&nbsp;
<ul>
<li>Total Prevalent Cases of Wet Age-related Macular Degeneration</li>
<li>Gender-specific Cases of Wet Age-related Macular Degeneration</li>
<li>Age-specific Cases of Wet Age-related Macular Degeneration</li>
</ul>
&nbsp;
Wet Age-related Macular Degeneration Epidemiological Insights Observed in 2020
&nbsp;
<ul>
<li class="ql-align-justify">The total diagnosed Wet Age-related Macular Degeneration prevalent population in 7MM was 4,426,968.</li>
<li class="ql-align-justify">In the US, Wet Age-related Macular Degeneration was Gender-specific prevalent cases observed in males were 539,922, whereas, in females, 1,002,711 cases were observed.&nbsp;</li>
<li class="ql-align-justify">The prevalent cases of Wet Age-related Macular Degeneration in the United States were 1,542,633.</li>
<li>The Wet Age-related Macular Degeneration prevalent cases in Japan were 813,974.</li>
<li>The number of Wet Age-related Macular Degeneration prevalent cases in Germany was observed to be 563,881.</li>
<li>The number of Wet Age-related Macular Degeneration prevalent cases in Italy was 419,403.</li>
</ul>
&nbsp;
<a style="color: #002966; background-color: transparent;" href="https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market" target="_blank" rel="noopener noreferrer">Wet Age-related Macular Degeneration Market</a>
In 2020, it was observed that the market size of Wet Age-related Macular Degeneration was expected to reach USD 7,459 million across the 7MM during the study period (2018&ndash;2030).
&nbsp;
Wet Age-related Macular Degeneration Market Drivers
&nbsp;
<ul>
<li>Drugs in pipeline</li>
<li>Personalized treatment</li>
<li>Increased prevalence&nbsp;</li>
<li>Genetic therapy</li>
</ul>
&nbsp;
&nbsp;Wet Age-related Macular Degeneration Market Barriers
&nbsp;
<ul>
<li>Cost of therapy</li>
<li>Launch of biosimilars</li>
<li>Future competition among similar drugs</li>
</ul>
&nbsp;
Wet Age-related Macular Degeneration Emerging Drugs
The emerging drugs of the Wet Age-related Macular Degeneration market are
&nbsp;
<ul>
<li>Faricimab</li>
<li>Conbercept</li>
<li>KSI-301</li>
<li>OPT-302</li>
<li>AKST4290</li>
<li>Sunitinib Malate</li>
<li>RGX-314</li>
<li>PAN-90806</li>
<li>Axitinib</li>
<li>HMR59</li>
<li>RBM-007 and others.</li>
</ul>
&nbsp;
Wet Age-related Macular Degeneration Key Players
The key players working in the Wet Age-related Macular Degeneration market are&nbsp;
&nbsp;
<ul>
<li>Roche</li>
<li>Chengdu Kanghong Biotech</li>
<li>Kodiak Sciences Inc.</li>
<li>Opthea Limited</li>
<li>Alkahest Inc.</li>
<li>Graybug Vision</li>
<li>REGENXBIO</li>
<li>PanOptica, Inc.</li>
<li>Clearside Biomedical</li>
<li>Hemera Biosciences</li>
<li>Ribomic USA Inc. and others.</li>
</ul>
&nbsp;
&nbsp;

Wet-Age Related Macular Degeneration Market

Wet-Age Related Macular Degeneration Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape.